Improving the viability of pseudo-islet for efficient insulin production
Journal of Diabetes & Metabolism

Journal of Diabetes & Metabolism
Open Access

ISSN: 2155-6156


Improving the viability of pseudo-islet for efficient insulin production

16th Global Diabetes Conference & Medicare Expo

March 22-23, 2017 Rome, Italy

Khalid M Alwsaidi, Ali Howaidi, Ying Yang and Ajile Elttayef

Imam Muhammad Bin Saud Islamic University, Saudi Arabia
Keele University, UK

Posters & Accepted Abstracts: J Diabetes Metab

Abstract :

A novel solution for type 1 diabetes mellitus (T1DM) is the formation of pseudo-islet cell, which are beta cells aggregations that mimic the basic function of beta cells. Central necrosis of pseudo-islet cell due to the shortage of the oxygen and nutrient transportation has been an obstacle to introduce this solution for the patient with T1DM. This study aims to overcome the issue by removing the central area of the pseudo-islets and replacing it with the cell-friendly alginate hydrogel â??gelatin beadsâ? type B (GBs), which is characterized by providing a high diffusion rate, and capable to function as a drug carrier. In order to maximize the diffusion rate and avoid the dissolution of the beads in the water solution, it is important to control the right size, shape of GBs and the crosslinkage time. Increase in viability and morphology is seen in the 30 ?¼m GBs cross-linked for six hours. The rat pancreatic ?² cell line BRIN-BD11 cells were grown in RPMI 1640 media and showed similar morphology of the native human islet cells after the GBs incorporation. Alexa Fluor 568 conjugate was used as a secondary antibody in the fluorescence test to examine the drug releasing capability of the GBs. The effect of the anti-inflammatory cytokine IL-10 on pseudo-islets can be determined by using dose response which reveals the best response at 10 ng/ml concentration. Improving our understanding of the methods used to remodel pseudoislets is needed to make possible strategies for developing de novo islet cells for therapeutic applications.

Biography :

Email: [email protected]